Well, looking at their financials, they're not in good shape based on what I was led to believe sometime in mid 2019 where CEO stated they have operational funds for 2 years, it looks like they went through their cash really quickly.
Their revenue is anemic, good thing that float is low but they'll either have to dilute to raise funds or some warrants through shareholders/investors or look for financing elsewhere.
No idea if it is getting accumulated, I'm underwater still and hoping for some good news here, they're definitely less in debt than the other one and much further in R&D, with fulltime staff, lab and promising developments.
$CNBX
News 
Market Data 
Discover 
